UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
April 11, 2017 (April 11, 2017)
Date of Report (Date of earliest event reported)
HELIUS MEDICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
| | | | |
| WYOMING | | 000-55364 | | 36-4787690 |
(State or other jurisdiction of incorporation or organization) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
(Exact name of registrant as specified in charter)
Suite 400, 41 University Drive
Newtown, Pennsylvania, 18940
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (215) 809-2018
Check the appropriate box below if theForm 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant toRule 14a-12 under the Exchange Act (17 CFR240.14a-12) |
| ☐ | Pre-commencement communications pursuant toRule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant toRule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Item 5.08 Shareholder Director Nominations
On April 11, 2017, the Board of Directors of Helius Medical Technologies, Inc (the “Company”) determined that the Company’s 2017 Annual Meeting of Shareholders (the “Annual Meeting”) will be held on June 5, 2017 at 10:00 a.m. local time at Sheraton Bucks County Hotel, 400 Oxford Valley Road, Langhorne, PA 19047, or at such other location as the Board may determine and set forth in the Company’s proxy statement for the Annual Meeting. The Board also set April 12, 2017 as the record date for determining shareholders entitled to receive notice of, and vote at, the meeting.
Because the Annual Meeting will be held more than 30 days prior to the date of the anniversary of the Company’s 2016 Annual Meeting of Shareholders, the deadline for any shareholder proposal or shareholder nomination under the rules of the Securities and Exchange Commission (the “SEC”) listed in the Company’s 2016 Proxy Statement on Schedule 14A, as filed with the SEC on August 16, 2016, is no longer applicable. Any such shareholder proposal or nomination, including any notice on Schedule 14N, intended to be considered for inclusion in the Company’s proxy materials for the Annual Meeting, must be received by the Company at its principal executive offices by no later than April 21, 2017, and directed to the attention of the Company’s Secretary. Other requirements for inclusion in the Company’s proxy materials are set forth in the rules and regulations promulgated by the SEC and the Company’s bylaws. Shareholders may contact the Company’s Secretary to obtain a copy of the relevant bylaw provisions regarding the requirements for making shareholder nominations and proposals.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | HELIUS MEDICAL TECHNOLOGIES, INC. |
| | | |
| Dated: April 11, 2017 | | | | By: | | /s/ Joyce LaViscount |
| | | | | | Joyce LaViscount, Chief Financial Officer |
3
